Welcome to SciBase Capital Markets Day 2024

SciBase has evolved from being an innovation company originating from the Karolinska Institute to a global company dedicated to supporting healthcare professionals in their work by facilitating early detection and prevention of skin cancer and other dermatological conditions. During SciBase’s Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will… Welcome to SciBase Capital Markets Day 2024 weiterlesen

SciBase capital markets day 2024 – save the date

SciBase has gone from being an innovation Company originating from the Karolinska Institute to a global company that supports physicians in their work by enabling early detection and prevention in skin cancer and other skin diseases. During SciBase’s capital markets day, Pia Renaudin, CEO since October 2023, will discuss SciBase’s way forward, updated strategy and… SciBase capital markets day 2024 – save the date weiterlesen

Skin Cancer and Reconstructive Surgery Center of California Adopts AI-driven Nevisense for early skin cancer detection

„Through our new partnership with Nevisense, we are now one of the first groups in the country to adopt AI technology that will help our clinicians improve patient outcomes,“ said Dr. Simon Madorsky, medical director and founder of the Skin Cancer and Reconstructive Surgery Center. Dr. Madorsky is also the CME Chair of the SCARS… Skin Cancer and Reconstructive Surgery Center of California Adopts AI-driven Nevisense for early skin cancer detection weiterlesen

SciBase and Skin and Cancer Institute partner to advance AI-driven skin cancer detection in California

„We are excited to integrate the Nevisense test during routine skin exams in several of our California offices and offer our patients the latest AI-driven technology for the earliest possible detection of melanoma.  Melanoma is the deadliest form of skin cancer, but when detected early, treatment has a nearly 100% cure rate.  Early testing and… SciBase and Skin and Cancer Institute partner to advance AI-driven skin cancer detection in California weiterlesen

Nomination Committee appointed for SciBase Holding’s Annual General Meeting in 2024

Thomas Axelsson (Gell Group), Dharminder Chahal (VanHerk Group), Peter Elmvik (Stockholms Elbolag), Tord Lendau (Chairman of the Board). The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on May 17, 2023. The Annual… Nomination Committee appointed for SciBase Holding’s Annual General Meeting in 2024 weiterlesen

Nevisense detects skin barrier damage from skin models in research

Skin barrier research comprises one of the fastest-growing fields within the dermatology community, including the development of new therapeutics, testing cosmetics, and beauty products, testing other consumer goods, and the scientific investigation of diseases related to the skin barrier. Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used to assess the effect of… Nevisense detects skin barrier damage from skin models in research weiterlesen

Nevisense detects skin barrier dysfunction in children with Atopic Dermatitis

Atopic Dermatitis is one of the most prevalent disorders in the world, affecting up to 20% of children globally. Currently, there is no clinical device that can assist in the diagnosis or severity assessment of AD.   The study was performed on children between 4 months and 3 years of age and aimed at identifying… Nevisense detects skin barrier dysfunction in children with Atopic Dermatitis weiterlesen

SciBase initiates pilot with Bare Dermatology to advance skin cancer detection in Texas

„At Bare Dermatology, we strive to provide our patients with the highest standard of care. Nevisense can help us to identify melanoma at an early stage, which is critical for improving patient outcomes. Melanoma is a leading cause of death among skin cancers, but when detected early, it has a nearly 100% cure rate. Our… SciBase initiates pilot with Bare Dermatology to advance skin cancer detection in Texas weiterlesen

SciBase strengthens US team with experienced Dermatology executive

Dan was previously Senior Director Commercial Insights, Market Access and Field Reimbursement at Biofrontera Inc., a company focused on the Dermatology market treating actinic keratosis with PDT (Photodynamic Therapy). At Biofrontera Inc., Dan was an instrumental leader in launching the new company in the US market with their first FDA approved drug and device combination… SciBase strengthens US team with experienced Dermatology executive weiterlesen

SciBase appoints Pia Renaudin as Chief Executive Officer

Pia will join SciBase as CEO on October 1st, 2023. As previously announced on May 15th, Simon Grant resigned from his position as CEO for personal reasons and will remain with the Company until the end of October to fully support the transition.  Pia is an exceptionally well-suited candidate to implement SciBase’s strategy in order… SciBase appoints Pia Renaudin as Chief Executive Officer weiterlesen

Besucheradresse